Nature Reviews Cancer最新文献_第10页

Lactate promotes DNA repair 乳酸盐促进 DNA 修复

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-08-05 DOI: 10.1038/s41568-024-00732-4

Daniela Senft

引用次数: 0

Publisher Correction: Structural variations in cancer and the 3D genome 出版商更正：癌症和三维基因组的结构变异。

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-08-05 DOI: 10.1038/s41568-024-00738-y

Frank Dubois, Nikos Sidiropoulos, Joachim Weischenfeldt, Rameen Beroukhim

引用次数: 0

Shared immunosuppressive mechanism between pregnancy and cancer 妊娠与癌症之间存在共同的免疫抑制机制。

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-08-01 DOI: 10.1038/s41568-024-00731-5

Linda Gummlich

引用次数: 0

Rational combination of cancer therapies with PD1 axis blockade 癌症疗法与 PD1 轴阻断剂的合理组合

IF 78.5 1区医学

Nature Reviews Cancer Pub Date : 2024-07-30 DOI: 10.1038/s41568-024-00727-1

引用次数: 0

Circular RNA in cancer 癌症中的环状 RNA

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-07-29 DOI: 10.1038/s41568-024-00721-7

Vanessa M. Conn, Arul M. Chinnaiyan, Simon J. Conn

{"title":"Circular RNA in cancer","authors":"Vanessa M. Conn, Arul M. Chinnaiyan, Simon J. Conn","doi":"10.1038/s41568-024-00721-7","DOIUrl":"10.1038/s41568-024-00721-7","url":null,"abstract":"Over the past decade, circular RNA (circRNA) research has evolved into a bona fide research field shedding light on the functional consequence of this unique family of RNA molecules in cancer. Although the method of formation and the abundance of circRNAs can differ from their cognate linear mRNA, the spectrum of interacting partners and their resultant cellular functions in oncogenesis are analogous. However, with 10 times more diversity in circRNA variants compared with linear RNA variants, combined with their hyperstability in the cell, circRNAs are equipped to influence every stage of oncogenesis. This is an opportune time to address the breadth of circRNA in cancer focused on their spatiotemporal expression, mutations in biogenesis factors and contemporary functions through each stage of cancer. In this Review, we highlight examples of functional circRNAs in specific cancers, which satisfy critical criteria, including their physical co-association with the target and circRNA abundance at stoichiometrically valid quantities. These considerations are essential to develop strategies for the therapeutic exploitation of circRNAs as biomarkers and targeted anticancer agents. Circular RNAs, once considered by-products of splicing errors, are now accepted as key players in cancer biology. In this Review, Conn et al. review the functional interactome of circular RNAs in cancer, highlighting their contribution to oncogenesis, their potential as biomarkers and the prospect of leveraging them for novel therapeutics.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 9","pages":"597-613"},"PeriodicalIF":72.5,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141790950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance 通过工程选择性抗药性增强癌症细胞免疫疗法

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-07-24 DOI: 10.1038/s41568-024-00723-5

Nils Wellhausen, Joanne Baek, Saar I. Gill, Carl H. June

{"title":"Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance","authors":"Nils Wellhausen, Joanne Baek, Saar I. Gill, Carl H. June","doi":"10.1038/s41568-024-00723-5","DOIUrl":"10.1038/s41568-024-00723-5","url":null,"abstract":"Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as a promising approach for achieving long-term remissions in patients with cancer. To be effective, the engineered cells must persist at therapeutically relevant levels while avoiding off-tumour toxicities, which has been challenging to realize outside of B cell and plasma cell malignancies. This Review discusses concepts to enhance the efficacy, safety and accessibility of cellular immunotherapies by endowing cells with selective resistance to small-molecule drugs or antibody-based therapies to facilitate combination therapies with substances that would otherwise interfere with the functionality of the effector cells. We further explore the utility of engineering healthy haematopoietic stem cells to confer resistance to antigen-directed immunotherapies and small-molecule targeted therapies to expand the therapeutic index of said targeted anticancer agents as well as to facilitate in vivo selection of gene-edited haematopoietic stem cells for non-malignant applications. Lastly, we discuss approaches to evade immune rejection, which may be required in the setting of allogeneic cell therapies. Increasing confidence in the tools and outcomes of genetically modified cell therapy now paves the way for rational combinations that will open new therapeutic horizons. Adoptive cell therapies have emerged as promising approaches for the treatment of patients with cancer. Engineering cell therapies to confer resistance to small-molecule therapies, chemotherapies and antibody-based therapies will improve their utility and success. Here, Wellhausen, Baek and colleagues outline the key principles of engineering resistance and potential applications for haematopoietic stem cell transplantation and allogeneic immune cell therapies.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 9","pages":"614-628"},"PeriodicalIF":72.5,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141754705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pre-empting drug resistance 预防耐药性

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-07-24 DOI: 10.1038/s41568-024-00729-z

Anna Dart

引用次数: 0

The impact of sex on metastasis 性别对转移的影响

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-07-22 DOI: 10.1038/s41568-024-00725-3

Yingsheng Zhang, Xue Li

引用次数: 0

In-depth organoid profiling of pancreatic cancer 胰腺癌的深度类器官图谱分析

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-07-09 DOI: 10.1038/s41568-024-00726-2

Ju Eun Maeng, Ja-Lok Ku

引用次数: 0

Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart 免疫检查点抑制剂介导的心肌炎：心脏中的 CTLA4、PD1 和 LAG3

IF 72.5 1区医学

Nature Reviews Cancer Pub Date : 2024-07-09 DOI: 10.1038/s41568-024-00715-5

Amir Z. Munir, Alan Gutierrez, Juan Qin, Andrew H. Lichtman, Javid J. Moslehi

{"title":"Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart","authors":"Amir Z. Munir, Alan Gutierrez, Juan Qin, Andrew H. Lichtman, Javid J. Moslehi","doi":"10.1038/s41568-024-00715-5","DOIUrl":"10.1038/s41568-024-00715-5","url":null,"abstract":"Immune-checkpoint inhibitors (ICIs) have revolutionized oncology, with nearly 50% of all patients with cancer eligible for treatment with ICIs. However, patients on ICI therapy are at risk for immune-related toxicities that can affect any organ. Inflammation of the heart muscle, known as myocarditis, resulting from ICI targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4), programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1) is an infrequent but potentially fatal complication. ICI-mediated myocarditis (ICI-myocarditis) is a growing clinical entity given the widespread use of ICIs, its increased clinical recognition and growing use of combination ICI treatment, a well-documented risk factor for ICI-myocarditis. In this Review, we approach ICI-myocarditis from a basic and mechanistic perspective, synthesizing the recent data from both preclinical models and patient samples. We posit that mechanistic understanding of the fundamental biology of immune-checkpoint molecules may yield new insights into disease processes, which will enable improvement in diagnostic and therapeutic approaches. The syndrome of ICI-myocarditis is novel, and our understanding of immune checkpoints in the heart is in its nascency. Yet, investigations into the pathophysiology will inform better patient risk stratification, improved diagnostics and precision-based therapies for patients. Despite the success of immune-checkpoint inhibitors, many patients are at risk of developing immune-related adverse events. One of these is myocarditis or inflammation of the heart. Munir, Gutierrez and colleagues describe the data from preclinical models and patient samples, which have begun to provide a mechanistic understanding of myocarditis resulting from immune-checkpoint inhibitors, and present suggestions for improving both the diagnosis and treatment of patients experiencing this immune-related toxicity.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 8","pages":"540-553"},"PeriodicalIF":72.5,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141561410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0